Sundar Jagannath, MBBS
img_Sundar Jagannath
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Specialties
Internal Medicine, Cancer (Oncology)

MD, University of Baroda

Residency, Internal Medicine, Bronx-Lebanon Hospital Center

Residency, Internal Medicine, BronxCare Hospital Center

Residency, Internal Medicine, Wayne State University

Residency, Medical Oncology, University of Texas MD Anderson Cancer Center

Certifications

American Board of Internal Medicine
Publications

Selected Publications

Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression. Junia Vieira dos Santos, David T. Melnekoff, Adolfo Aleman, Tarek H. Mouhieddine, Rocio Montes de Oca, Feng Wang, Sridevi Rajeeve, Sherry Bhalla, Oliver Van Oekelen, Bhaskar Upadhyaya, Yogita Ghodke-Puranik, Violetta Leshchenko, Seunghee Kim-Schulze, Adeeb Rahman, Shaked Afik, Hadas Lewinsky, Vicki Plaks, Santiago Thibaud, Hearn Jay Cho, Joshua Richter, Cesar Rodriguez, Larysa Sanchez, Adriana Rossi, Shambavi Richard, Ajai Chari, Deepu Madduri, Sundar Jagannath, Samir Parekh, Alessandro Laganà. Blood advances

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Hans C. Lee, Jeffrey A. Zonder, Madhav V. Dhodapkar, Sundar Jagannath, James E. Hoffman, Attaya Suvannasankha, Mansi R. Shah, Suzanne Lentzsch, Rachid Baz, Joseph J. Maly, Swathi Namburi, Matthew J. Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca Silbermann, Chang Ki Min, Marie Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez-Lopez, Michelle DeVeaux, Tito Roccia, Dhruti Chokshi, Megan Seraphin, Kate Knorr, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Naresh Bumma, Joshua Richter. Clinical Lymphoma, Myeloma and Leukemia

Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Hans C. Lee, Naresh Bumma, Joshua Richter, Jeffrey A. Zonder, James E. Hoffman, Zheng Yi Zhou, Viviana García-Horton, Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Wenxin Ma, Timothy J. Inocencio, Yingxin Xu, Evelien Bergrath, James Harnett, Tito Roccia, Kate Knorr, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Sundar Jagannath. Clinical Lymphoma, Myeloma and Leukemia

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Jagannath during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Genentech, Inc.
  • GSK plc.
  • Caribou Biosciences, Inc.
  • Takeda Pharmaceuticals Of North America, Inc.
  • Bristol-Meyers Company
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi US Services Inc.
  • Janssen Services LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.